MYC and diffuse large B-cell lymphoma: Furthermore, using the lipid metabolism prognostic model we determined novel subtypes featured by distinct lipid metabolism profiles and found that drugs that compromising MYC target genes rather than immune checkpoint inhibitors may be beneficial to DLBCL patients with specific lipid metabolism status.